Loading company…
SHIP develops vaccines and biopharmaceutical products.
Founded in 2017 and based in Suzhou, China, SHIP researches and develops human vaccines and biopharmaceutical products. Its platforms include recombinant protein antigen and peptide polysaccharide conjugate vaccines, and its pipeline includes more than ten preventive and therapeutic products. A Phase III clinical trial of YD101 began in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in